Iradimed (IRMD) EBITDA Margin (2013 - 2026)

Iradimed (IRMD) has 14 years of EBITDA Margin data on file, last reported at 32.93% in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 32.93%, up 509.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 9.0% (down 2114.0% YoY), and the FY2025 annual result was 7.11%, down 2288.0% from the prior year.
• EBITDA Margin grew to 32.93% in Q1 2026 per IRMD's latest filing, from 57.72% in the prior quarter.
• Over five years, EBITDA Margin peaked at 35.78% in Q3 2023 and troughed at 57.72% in Q4 2025.
• A 5-year average of 25.15% and a median of 30.77% in 2023 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2022 and 2025: EBITDA Margin soared 1395 bps in 2022, then tumbled 8763 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 28.62% in 2022, then increased by 3 bps to 29.57% in 2023, then grew by 1 bps to 29.92% in 2024, then tumbled by 293 bps to 57.72% in 2025, then jumped by 157 bps to 32.93% in 2026.
• Business Quant data shows IRMD's EBITDA Margin at 32.93% in Q1 2026, 57.72% in Q4 2025, and 32.23% in Q3 2025.